ReviewWorld journal of gastroenterology2010
Difficult treatment decisions in autoimmune hepatitis.
Review in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 75 citations in OpenAlex.
- Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis.Hepatology communications · 2026Article
- A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis-Can We Draw a Line?Clinics and practice · 2023Article
- Therapeutic effects of dexamethasone-loaded hyaluronan nanogels in the experimental cholestasis.Drug delivery and translational research · 2022Article
- Article
- Infectious complications and timing for liver transplantation in autoimmune acute liver failure in Japan: a subanalysis based on nationwide surveys between 2010 and 2015.Journal of gastroenterology · 2020Article
- Rituximab-induced autoimmune hepatitis: A case study and literature review.Canadian liver journal · 2020Article
- Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis.Pediatric gastroenterology, hepatology & nutrition · 2020Article
- [Standard treatment of autoimmune hepatitis: experience from rheumatoid arthritis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children.Przeglad gastroenterologiczny · 2016Article
- Autoimmune Hepatitis in Hawai'i.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2015Article
- Autoimmune hepatitis.Frontiers of medicine · 2015Review
- Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids.World journal of hepatology · 2014Review
- Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis.World journal of gastroenterology · 2014Article
- Challenges in the diagnosis and management of autoimmune hepatitis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Review
- Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure.Hepatology international · 2013Article
- Overlap syndromes of autoimmune hepatitis: an open question.Digestive diseases and sciences · 2013Review
- Advances in the current treatment of autoimmune hepatitis.Digestive diseases and sciences · 2012Review
- Diagnosis and treatment of autoimmune hepatitis.Current gastroenterology reports · 2012Review
- Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.Autoimmune diseases · 2012Article
- Treatment of Fulminant Autoimmune Hepatitis: Corticosteroid Therapy or Liver Transplantation? A Case Report and Literature Review.Gastroenterology research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment decisions in autoimmune hepatitis are complicated by the diversity of its clinical presentations, uncertainties about its natural history, evolving opinions regarding treatment end points, varied nature of refractory disease, and plethora of alternative immunosuppressive agents. The goals of this article are to review the difficult treatment decisions and to provide the bases for making sound therapeutic judgments. The English literature on the treatment problems in autoimmune hepatitis were identified by Medline search up to October 2009 and 32 years of personal experience. Autoimmune hepatitis may have an acute severe presentation, mild inflammatory activity, lack autoantibodies, exhibit atypical histological changes (centrilobular zone 3 necrosis or bile duct injury), or have variant features reminiscent of another disease (overlap syndrome). Corticosteroid therapy must be instituted early, applied despite the absence of symptoms, or modified in an individualized fashion. Pursuit of normal liver tests and tissue is the ideal treatment end point, but this objective must be tempered against the risk of side effects. Relapse after treatment withdrawal requires long-term maintenance therapy, preferably with azathioprine. Treatment failure or an incomplete response warrants salvage therapy that can include conventional medications in modified dose or empirical therapies with calcineurin inhibitors or mycophenolate mofetil. Liver transplantation supersedes empirical drug therapy in decompensated patients. Elderly and pregnant patients warrant treatment modifications. Difficult treatment decisions in autoimmune hepatitis can be simplified by recognizing its diverse manifestations and individualizing treatment, pursuing realistic goals, applying appropriate salvage regimens, and identifying problematic patients early.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.